Background: Rapid improvement in HbA1c has been associated with significant short-term worsening of diabetic retinopathy. Flash monitoring (FM) is associated with significant improvement in HbA1c, particularly in those with high HbA1c at baseline.

Methods: We identified all adults with type 1 diabetes, using NHS reimbursed FM, attending our center. This assessment was limited to those with high microvascular risk defined as duration of diabetes > 3 years and pre-FM HbA1c >9%. From this cohort 40 individuals were selected with the largest post-FM fall in HbA1c (responders) and compared with a further 35 with the smallest change in HbA1c (non-responders). Information on retinopathy status and laser photocoagulation was derived from electronic patient records.

Results: Baseline HbA1c was significantly higher in the responder category (10.5 vs. 9.8%, P = 0.002). Median change in HbA1c, following FM, was -2.5% in responders and +0.2% in non-responders. At baseline, 32% had retinopathy classed as more severe than background (25% had proliferative retinopathy). Median duration from FM commencement to next ophthalmological assessment was 36 weeks (IQR 16 - 50). The percentage with worsening retinopathy did not significantly differ between responders (18%) and non-responders (11%) (P = 0.458). The percentage requiring laser photocoagulation after FM commencement did not differ between responders (17.5%) and non-responders (14.3%) (P = 0.704). Logistic regression analysis identified previous laser (OR 19.9, P = 0.001) but not baseline HbA1c (P = 0.139), age (P = 0.115) or HbA1c response after FM (P = 0.473) as predictive of requiring laser photocoagulation after FM commencement.

Discussion: These data suggest that rapid improvement in HbA1c following FM, in a high-risk population, is not independently predictive of subsequent requirement for laser photocoagulation.

Disclosure

K. Linton: None. F.W. Gibb: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.